CTLA4 and neoplasm: ICIs act inhibiting tumor immune escape by targeting PD-1 and its ligand (PD-L1), lymphocyte-activating gene-3 (LAG3), cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), and other targets [212].